RxDoctor Payments Data

George Wandling, MD

Ophthalmology · Coon Rapids, MNNPI 1083935068

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (45.9%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. Glaukos Corporation accounts for 91.4% of it on its own, with 8 other manufacturers making up the rest. 2025 is the largest year on record at $8,944, 3.7 times the $2,425 reported in 2019. Among ophthalmology clinicians in MN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$15,046in general payments, 2019–2025

Across 61 payments — averaging $246.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Glaukos Corporation$14K
  • Alcon$544
  • Ivantis, Inc$315
  • Sight Sciences, Inc.$133
  • AstraZeneca$113
  • Rxsight Inc$74
  • plus $111 from 3 others
$368,231in research payments, 2019–2025

Across 340 payments — averaging $1083.03 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Alcon Research LLC$333K
  • Glaukos Corporation$31K
  • Ivantis, Inc$4K

What the payments were for

  • Consulting fees$6,90046%
  • Speaking & faculty fees$4,53230%
  • Travel & lodging$1,1688%
  • Food & beverage$2,34516%
  • Gifts$1001%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,046 in reported general payments places this provider in the 90th percentile of 330 ophthalmology providers in Minnesota.

See all ophthalmology providers in Minnesota

Medicare billing

Part B allowed, 2024
$241,755
Medicare patients
309
Services billed
1,124

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Prednisolone Acetate410$13,411
Ketorolac Tromethamine364$6,147
Ofloxacin366$4,987
Latanoprost198$2,046
ValacyclovirValacyclovir Hcl34$1,365
Timolol Maleate53$874
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat29$501
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha20$314
Brimonidine Tartrate16$153

Paid to pharmacies, not to this prescriber.

Other ophthalmology in Coon Rapids

See the full list for Minnesota

Where these figures come from

Is this you, or does something look wrong? →